- Bracco Imaging’s VueJect, its first ultrasound contrast delivery system designed specifically for cardiology imaging, received FDA 510(k) clearance and Health Canada authorization. The system will initially launch in the US and Canada.
- VueJect is designed to streamline contrast administration, reduce operator variability and enable continuous administration of ultrasound contrast agents, supporting more consistent enhancement during cardiac imaging procedures.
- The dedicated injector expands Bracco’s contrast-enhanced ultrasound (CEUS) ecosystem and can administer Lumason/SonoVue in dilution during echocardiography procedures, providing cardiac sonographers with a standardized approach to contrast administration.
- The regulatory milestones mark the first step in Bracco’s global commercialization strategy for VueJect. The company is preparing for commercial launch in North America, with additional regulatory submissions planned in other markets
Takeaways:
Bracco’s VueJect is the first dedicated injector for cardiac ultrasound contrast, so it can make echocardiograms with Lumason/SonoVue more consistent, less dependent on who is doing the injection, and easier to run continuously during the exam. By standardizing how contrast is given, it can improve image quality and workflow in busy labs, potentially reducing repeat scans and making contrast‑enhanced ultrasound a more practical alternative to costlier imaging like CT or MRI for certain heart assessments.
Source: PRnewswire
